A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)

被引：0
|
作者：
Andersen, C. [1 ]
Mortensen, N. [1 ]
Vestergaard, H. [2 ]
Bjerrum, O. [3 ]
Klausen, T. [4 ]
Hasselbalch, H. [1 ]
机构：
[1] Roskilde Univ Hosp, Dept Haematol, Roskilde, Denmark
[2] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[3] Copenhagen Univ Hosp, Dept Haematol, Copenhagen, Denmark
[4] Herlev Hosp, Dept Haematol, Herlev, Denmark
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P279
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [21] PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS (POST-ET MF
    Pemmaraju, N.
    Kantarjian, H.
    Cortes, J.
    Kadia, T.
    DiNardo, C.
    Estrov, Z.
    Pierce, S.
    Zhou, L.
    Salinas, K.
    Tuttle, C.
    Mak, P. Y.
    Carter, B. Z.
    Verstovsek, S.
    HAEMATOLOGICA, 2016, 101 : 95 - 95
  • [22] Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF)
    Harrison, C. N.
    Kiladjian, J.
    Al-Ali, H. K.
    Gisslinger, H.
    Waltzman, R. J.
    Stalbovskaya, V.
    McQuitty, M.
    Hunter, D. S.
    Levy, R. S.
    Cervantes, F.
    Vannucchi, A. M.
    Barbui, T.
    Barosi, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [23] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [24] PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
    Harrison, C.
    Szoke, A.
    Suvorov, A.
    Egyed, M.
    Prasad, R.
    Mayer, J.
    Jakucs, J.
    Elinder, A.
    Recher, C.
    te Boekhorst, P. A.
    Knapper, S.
    Somervaille, T.
    Ciceri, F.
    Quddus, F.
    Straetmans, N.
    Niederwieser, D.
    Dean, J. P.
    Granston, T.
    Kiladjian, J. J.
    Vannucchi, A.
    Nangalia, J.
    Mead, A.
    Mesa, R.
    HAEMATOLOGICA, 2015, 100 : 103 - 103
  • [25] A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 x 109/l
    Gisslinger, Heinz
    McMullin, Mary Frances
    Jaekel, Nadja
    Miller, Carole Brennan
    Verstovsek, Srdan
    Harrison, Claire N.
    Barosi, Giovanni
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa-Kathrin
    Weber, Denis
    Hu, Jing
    Sirulnik, L. Andres
    Vannucchi, Alessandro M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)
    Pemmaraju, Naveen
    Carter, Bing Z.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Bose, Prithviraj
    Pierce, Sherry
    Zhou, Lingsha
    Estrov, Zeev
    Tuttle, Carla Kay
    Salinas, Karina
    Mak, Po Yee
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [27] A PHASE 1B, DOSE-FINDING STUDY OF RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS (MF), POST-POLYCYTHEMIA VERA MF (PPV-MF), OR POST-ESSENTIAL (PET-MF) THROMBOCYTHEMIA MF
    Harrison, N.
    Kiladjian, J. J.
    Passamonti, F.
    Vannucchi, A.
    Gadbaw, B.
    Acharyya, S.
    Woo, M.
    Liu, T.
    Sirulnik, A.
    Conneally, E.
    Giles, F.
    Kindler, T.
    Heidel, F.
    Ribrag, V.
    HAEMATOLOGICA, 2012, 97 : 146 - 146
  • [28] A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)
    Verstovsek, S.
    Kantarjian, H. M.
    Pardanani, A.
    Thomas, D. A.
    Cortes, J. E.
    Mesa, R.
    Hogan, W.
    Redman, J.
    Levy, R.
    Vaddi, K.
    Tefferi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [30] Primary myelofibrosis (PMF), post polycythernia vera myelotibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
    Mesa, Ruben A.
    Verstovsek, Srdan
    Cervantes, Francisco
    Barosi, Giovanni
    Reilly, John T.
    Dupriez, Brigitte
    Levine, Ross
    Le Bousse-Kerdiles, Marie-Caroline
    Wadleigh, Martha
    Campbell, Peter J.
    Silver, Richard T.
    Vannucchi, Alessandro M.
    Deeg, H. Joachim
    Gisslinger, Heinz
    Thomas, Deborah
    Odenike, Olatoyosi
    Solberg, Lawrence A.
    Gotlib, Jason
    Hexner, Elizabeth
    Nimer, Stephen D.
    Kantarjian, Hagop
    Orazi, Attilio
    Vardiman, James W.
    Thiele, Juergen
    Tefferi, Ayalew
    LEUKEMIA RESEARCH, 2007, 31 (06) : 737 - 740
12345